The results have shown a significant increase in CD25+ T cells in the tumor samples compared to non-tumor samples in CD4+ (p < 0.05), CD8+ (p < 0.001) and CD4+ CD8+ (p < 0.05) T cells, and a decrease on HLA-DR+ T-cells, being significant in CD4+ (p < 0.001), CD8+ (p < 0.001), and CD4+ CD8+ (p < 0.05) T cells (Figure 5). This evidence concerns the gene CD4 and neoplasm.